Ex-Al­ler­gan prez In­gram forges $1B deal to sell Alzheimer’s biotech to Brent Saun­ders and the new crew at Al­ler­gan

Brent Saun­ders, Al­ler­gan

Just a year af­ter ex-Al­ler­gan pres­i­dent Doug In­gram took the helm of a low-pro­file biotech named Chase Phar­ma­ceu­ti­cals and helped steer an ex­per­i­men­tal ther­a­py for Alzheimer’s through a suc­cess­ful, though small, Phase II study, he’s arranged a sale of the com­pa­ny to Brent Saun­ders and the new team run­ning Al­ler­gan.

Al­ler­gan CEO Saun­ders agreed to hand over $125 mil­lion in a cash up­front to ac­quire Irvine, CA-based Chase, and a spokesper­son for the com­pa­ny says mile­stones bring the to­tal val­ue of the deal up to a po­ten­tial $1 bil­lion.

Al­ler­gan gets a small pipeline, but the deal is be­ing dri­ven by its de­sire for CPC-201. While a num­ber of new drugs in the Alzheimer’s sec­tor are try­ing to bend the curve on dis­ease pro­gres­sion, CPC-201 has a much more mod­est goal in mind. The drug is de­signed to al­low pa­tients to height­en their dose of donepezil, which is used to help con­trol symp­toms of the mem­o­ry-wast­ing ail­ment.

Doug In­gram, Chase Phar­ma­ceu­ti­cals

The deal al­so spot­lights Al­ler­gan’s hunger for new drugs it can push in­to late-stage test­ing. It’s ac­quired a grow­ing line­up of biotechs in the months since its merg­er with Pfiz­er fell through. And Saun­ders has made it clear to me that this kind of steady flow of ac­qui­si­tions is a part of Al­ler­gan’s busi­ness mod­el now.

The deal marks a sig­nif­i­cant suc­cess for Chase’s in­vestors, which have backed the biotech with $24 mil­lion. The cash up­front is worth more than 5X, and there’s much, much more on the ta­ble if the Phase III works.

In­gram took over as CEO of Chase last fall, just months af­ter Saun­ders stepped in to merge the com­pa­ny in­to Ac­tavis, keep­ing the Al­ler­gan name in that buy­out. In­gram stepped out of his role at Al­ler­gan at the time, though he agreed to help as an ad­vis­er.

In Phase II, 29 out of 33 pa­tients were able to tol­er­ate a 40 mg max­i­mum dose of the drug with­out trig­ger­ing se­ri­ous side ef­fects. If that plays out in a much larg­er late-stage tri­al, Al­ler­gan be­lieves it will have a much-need­ed ther­a­py that can be added to the very lim­it­ed phar­ma­copeia that ex­ists cur­rent­ly in Alzheimer’s.

Bern­stein an­a­lysts gave the deal a quick thumbs up. They wrote:

Our view:  as­sum­ing the da­ta af­firms the news, this is cer­tain­ly an in­trigu­ing prod­uct and well worth the $125M spent on the ac­qui­si­tion.  A decade ago, this could have been a mul­ti-bil­lion block­buster drug.  Now, it seems more de­pen­dent on how good the amy­loid be­ta based drugs will be.  Still, we ex­pect that for pa­tients who are can­di­dates for Ari­cept, this could be an im­prove­ment.   Fur­ther, giv­en AGN ex­ist­ing com­mer­cial in­fra­struc­ture, the re­turn on in­vest­ment could be high.

“We be­lieve our lead can­di­date, CPC-201, will of­fer a sig­nif­i­cant im­prove­ment over ex­ist­ing ther­a­py in the symp­to­matic treat­ment of Alzheimer’s dis­ease, and will ben­e­fit all those suf­fer­ing from this dis­ease,” said Thomas Chase, co-founder and Chief Sci­en­tif­ic Of­fi­cer of Chase Phar­ma­ceu­ti­cals.

De­vel­op­ment of the Next Gen­er­a­tion NKG2D CAR T-cell Man­u­fac­tur­ing Process

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

Paul Hudson, Getty Images

UP­DAT­ED: Sanofi CEO Hud­son lays out new R&D fo­cus -- chop­ping di­a­betes, car­dio and slash­ing $2B-plus costs in sur­gi­cal dis­sec­tion

Earlier on Monday, new Sanofi CEO Paul Hudson baited the hook on his upcoming strategy presentation Tuesday with a tell-tale deal to buy Synthorx for $2.5 billion. That fits squarely with hints that he’s pointing the company to a bigger future in oncology, which also squares with a major industry tilt.

In a big reveal later in the day, though, Hudson offered a slate of stunners on his plans to surgically dissect and reassemble the portfoloio, saying that the company is dropping cardio and diabetes research — which covers two of its biggest franchise arenas. Sanofi missed the boat on developing new diabetes drugs, and now it’s pulling out entirely. As part of the pullback, it’s dropping efpeglenatide, their once-weekly GLP-1 injection for diabetes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.

Roger Perlmutter, Merck

#ASH19: Here’s why Mer­ck is pay­ing $2.7B to­day to grab Ar­Qule and its next-gen BTK drug, lin­ing up Eli Lil­ly ri­val­ry

Just a few months after making a splash at the European Hematology Association scientific confab with an early snapshot of positive data for their BTK inhibitor ARQ 531, ArQule has won a $2.7 billion buyout deal from Merck.

Merck is scooping up a next-gen BTK drug — which is making a splash at ASH today — from ArQule in an M&A pact set at $20 a share $ARQL. That’s more than twice Friday’s $9.66 close. And Merck R&D chief Roger Perlmutter heralded a deal that nets “multiple clinical-stage oral kinase inhibitors.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.

Left top to right: Mark Timney, Alex Denner, Vas Narasimhan. (The Medicines Company, Getty, AP/Endpoints News)

In a play-by-play of the $9.7B Med­Co buy­out, No­var­tis ad­mits it over­paid while of­fer­ing a huge wind­fall to ex­ecs

A month into his tenure at The Medicines Company, new CEO Mark Timney reached out to then-Novartis pharma chief Paul Hudson: Any interest in a partnership?

No, Hudson told him. Not now, at least.

Ten months later, Hudson had left to run Sanofi and Novartis CEO Vas Narasimhan was paying $9.7 billion for the one-drug biotech – the largest in the string of acquisitions Narasimhan has signed since his 2017 appointment.

The deal was the product of an activist investor and his controversial partner working through nearly a year of cat-and-mouse negotiations to secure a deal with Big Pharma’s most expansionist executive. It represented a huge bet in a cardiovascular field that already saw two major busts in recent years and brought massive returns for two of the industry’s most eye-raising names.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson. Sanofi

New Sanofi CEO Hud­son adds next-gen can­cer drug tech to the R&D quest, buy­ing Syn­thorx for $2.5B

When Paul Hudson lays out his R&D vision for Sanofi tomorrow, he will have a new slate of interleukin therapies and a synthetic biology platform to boast about.

The French pharma giant announced early Monday that it is snagging San Diego biotech Synthorx in a $2.5 billion deal. That marks an affordable bolt-on for Sanofi but a considerable return for Synthorx backers, including Avalon, RA Capital and OrbiMed: At $68 per share, the price represents a 172% premium to Friday’s closing.

Synthorx’s take on alternative IL-2 drugs for both cancer and autoimmune disorders — enabled by a synthetic DNA base pair pioneered by Scripps professor Floyd Romesberg — “fits perfectly” with the kind of innovation that he wants at Sanofi, Hudson said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.

Jake Van Naarden, Josh Bilenker, Nisha Nanda (Credit: Loxo, Aisling Capital)

Josh Bilenker and his Loxo crew are tak­ing the reins on on­col­o­gy R&D at Eli Lil­ly, culling the weak and map­ping a new path

Josh Bilenker, Jake Van Naarden and Nisha Nanda came out of Eli Lilly’s $8 billion Loxo Oncology buyout with a bundle of cash and plenty of choices on what they could do next. Start a new company, go public. Live on the beach in 5-star luxury. Contemplate the stars — in their own observatory.

So what are they doing?

They formed a new executive team that is taking over the management of Eli Lilly’s hundreds-strong oncology R&D group — essentially using Loxo as a base for a bold new experiment in Big Pharma R&D in an attempt to create a true biotech environment with the deep pockets of a top-15 industry player. They’ve recruited David Hyman from Memorial Sloan Kettering to join the team as chief medical officer. And the mandate includes culling out the oncology pipeline, highlighting their star prospects and going after new programs wherever they can find the best prospects.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.

Game on: Re­gen­eron's BC­MA bis­pe­cif­ic makes clin­i­cal da­ta de­but, kick­ing off mul­ti­ple myelo­ma matchup with Bris­tol-My­ers

As J&J attempts to jostle past Bristol-Myers Squibb and bluebird for a landmark approval of its anti-BCMA CAR-T — and while GlaxoSmithKline maps a quick path to the FDA riding on its own BCMA-targeting antibody-drug conjugates — the bispecifics are arriving on the scene to stake a claim for a market that could cross $10 billion per year.

The main rivalry in multiple myeloma is shaping up to be one between Regeneron and Bristol-Myers, which picked up a bispecific antibody to BCMA through its recently closed $74 billion takeover of Celgene. Both presented promising first-in-human data at the ASH 2019 meeting.

FDA lifts hold on Abeon­a's but­ter­fly dis­ease ther­a­py, paving way for piv­otal study

It’s been a difficult few years for gene and cell therapy startup Abeona Therapeutics. Its newly crowned chief Carsten Thiel was forced out last year following accusations of unspecified “personal misconduct,” and this September, the FDA imposed a clinical hold on its therapy for a form of “butterfly” disease. But things are beginning to perk up. On Monday, the company said the regulator had lifted its hold and the experimental therapy is now set to be evaluated in a late-stage study.

Roche faces an­oth­er de­lay in strug­gle to nav­i­gate Spark deal past reg­u­la­tors — but this one is very short

Roche today issued the latest in a long string of delays of its $4.3 billion buyout of Philadelphia-based Spark Therapeutics. The delay comes as little surprise — it is their 10th in as many months — as their most recent delay was scheduled to expire before a key regulatory deadline.

But it is notable for its length: 6 days.

Previous extensions had moved the goalposts by about 3 weeks to a month, with the latest on November 22 expiring tomorrow. The new delay sets a deadline for next Monday, December 16, the same day by which the UK Competition and Markets Authority has to give its initial ruling on the deal. And they already reportedly have lined up an OK from the FTC staff – although that’s only one level of a multi-step process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.